The COVID-19 NDoH Rapid Review committee has included baricitinib (Unamity®) on the COVID-19 Essential Medicines List. The guidelines are
developed by the Clinical Guidelines Subcommittee of the National Department of Health’s Incident Management Team. They are informed by rapid medicine reviews conducted by the National Essential Medicines List Committee’s Subcommittee on COVID-19, as well as advisories provided by the Ministerial Advisory Committee on COVID-19.
This communication is intended for the provision of information only, relative to planning for reimbursement and access decision making and/or facilitation of pricing discussion. It is not intended to influence prescribing habits or behaviour. Please note that the approved label is baricitinib for the treatment of coronavirus disease 2019 (COVID-19) in hospitalised adult and
paediatric patients aged 10 years and older who require supplemental oxygen.
You can access current Professional Information of baricitinib here.
Disclaimer: Meeting intended for South African Doctors and Nurses only